SA Transcripts • Fri, Nov. 7
SA News • Dec. 6, 2013
There are no Focus articles on MPSYF.
Dec. 6, 2013, 4:24 AM
- Novartis' (NVS) LBH589 drug for treating relapsed and refractory multiple myeloma, a bone marrow cancer, met its primary goal in a Phase III trial.
- When combined with two other therapies, bortezomib and dexamethasone, LBH589 significantly increased progression-free survival in patients compared with those treatments alone.
- Other companies working on drugs for multiple myeloma include Celgene (CELG) and German firm MorphoSys (MPSYF). (PR)
Aug. 20, 2013, 7:57 AM
- Novartis (NVS +2.4%) has received FDA breakthrough therapy designation for its BYM338 (bimagrumab) drug for treating sufferers of sporadic inclusion body myositis (sIBM), a rare yet potentially fatal muscle-wasting condition.
- If eventually authorized, BYM338 has the potential to become the first treatment for sIBM.
- BYM338 is the third Novartis drug this year to obtain the FDA's breakthrough designation. The company developed it with Morphosys (MPSYF.PK).
- Patients with sIBM can gradually lose their ability to walk, experience falls and injuries, lose hand function, and have swallowing difficulties. (PR)
Jun. 27, 2013, 7:45 AMCelgene (CELG) has entered into an alliance worth up to €628M, excluding royalties, with Germany's MorphoSys (MPSYF.PK) to develop the latter's MOR202 drug, including for treating the blood cancer multiple myeloma. Celgene will pay €70.8M upfront, €46.2M for new shares in MorphoSys and milestones, while the companies will also share profits. Earlier this month, MorphoSys signed a major licensing deal with GlaxoSmithKline. (PR) | Comment!
There are no StockTalks on this stock yet.
MPSYF vs. ETF Alternatives
MorphoSys developed HuCAL, the most successful antibody library technology in the pharmaceutical industry. By successfully applying this and other proprietary technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human... More
Other News & PR